Physician profile
Robert F Melendez
NPI 1316932742
$348,835.29
in general payments reported to CMS, 2019-2025
22 companies · $90K in 2025
The $90K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $3,978 · 2021: $21K · 2022: $113K · 2023: $35K · 2024: $86K · 2025: $90K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $129K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Travel and Lodging: $13K · Food and Beverage: $8,852 · Long Term Medical Supply Or Device Loan: $5,341 · Charitable Contribution: $2,700 · Gift: $40.85 · Honoraria: $25.59 · Other payment types: $10.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $129,113.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,171.50 |
| Travel and Lodging | $13,385.21 |
| Food and Beverage | $8,852.31 |
| Long Term Medical Supply Or Device Loan | $5,341.30 |
| Charitable Contribution | $2,700.00 |
| Gift | $40.85 |
| Honoraria | $25.59 |
| Other payment types | $10.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $261,028.15 | 2019-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Hydrus Microstent |
| Alcon Research LLC | $31,361.57 | 2021-2025 | Clareon, Argos, Acrysof Iq Panoptix Uv Iol |
| Glaukos Corporation | $21,391.13 | 2021-2025 | Idosetr, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Idose |
| Rxsight INC | $14,976.65 | 2021-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Carl Zeiss Meditec USA, INC. | $7,820.95 | 2021-2025 | Lumera 700, Quatera 700, Visumax |
| Tearlab Corp | $6,073.24 | 2021-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Bausch & Lomb Americas INC. | $2,701.83 | 2023-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Abbvie INC. | $1,524.71 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $597.65 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $485.69 | 2021-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $392.06 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Allergan, INC. | $184.25 | 2021-2022 | |
| Harrow Eye, LLC | $55.98 | 2024-2025 | Vevye, Iheezo |
| Oyster Point Pharma, INC. | $46.85 | 2022-2024 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $36.11 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $28.10 | 2021 | |
| Rayner Intraocular Lenses Limited | $26.82 | 2025 | Rayone Spheric, Rayner Cataract Set 1, Rayone Emv |
| Abb Con-Cise Optical Group LLC | $25.31 | 2021 | |
| Coherus Oncology, INC. | $22.96 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.50 | 2020 | |
| Aerie Pharmaceuticals, INC. | $17.98 | 2021 | |
| Ocular Therapeutix, INC. | $15.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Melendez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.